Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Accenture
Baxter
Harvard Business School
Chinese Patent Office
McKesson
Argus Health
McKinsey
Daiichi Sankyo

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BACLOFEN

« Back to Dashboard

Clinical Trials for Baclofen

Trial ID Title Status Sponsor Phase Summary
NCT00000303 Rapid Evaluation of Baclofen for Treatment of Cocaine Abuse/Dependence - 6 Completed National Institute on Drug Abuse (NIDA) Phase 2 The purpose of this study is to empirically test a series of medications to: 1) determine each medication's efficacy in treatment of cocaine abuse/dependence; 2) find most effective dose range for each medication. In this study, baclofen is tested.
NCT00000303 Rapid Evaluation of Baclofen for Treatment of Cocaine Abuse/Dependence - 6 Completed University of California, Los Angeles Phase 2 The purpose of this study is to empirically test a series of medications to: 1) determine each medication's efficacy in treatment of cocaine abuse/dependence; 2) find most effective dose range for each medication. In this study, baclofen is tested.
NCT00004431 Randomized Study of L-Baclofen in Patients With Refractory Trigeminal Neuralgia Completed University of Pittsburgh N/A OBJECTIVES: I. Evaluate the efficacy of L-baclofen in patients with refractory trigeminal neuralgia. II. Evaluate the safety and tolerance of L-baclofen in these patients.
NCT00082485 Baclofen for the Treatment of Cocaine Dependence - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 The purpose of this study is to assess the efficacy and safety of baclofen for the treatment of cocaine dependence.
NCT00139789 A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis Completed UCB Pharma Phase 3 This was a multicenter, open-label, randomized, crossover trial in subjects with MS who were already taking a stable dose of baclofen (up to 80 mg/day) for spasticity. The trial was designed to assess subject preference for Kemstro or conventional baclofen. At Visit 1, subjects were screened, and if qualified, were randomly assigned to one of two following treatment sequences: Kemstro/conventional baclofen or conventional baclofen/Kemstro.
NCT00142883 The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3 Terminated National Institute on Drug Abuse (NIDA) N/A Gamma-aminobutyric acid (GABA) is a type of neurotransmitter, which is a chemical that transmits information within and from the brain to all parts of the body. By lowering the level of another neurotransmitter called dopamine, GABA may have the ability to diminish cocaine cravings in addicts. The purpose of this study is to gather information on the interaction between cocaine and selected GABA enhancing medications in individuals addicted to cocaine. This may lead to future clinical studies using GABA medications to treat cocaine addiction.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Baclofen

Condition Name

Condition Name for Baclofen
Intervention Trials
Alcohol Dependence 9
Spasticity 7
Alcoholism 6
Cerebral Palsy 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Baclofen
Intervention Trials
Alcoholism 14
Muscle Spasticity 11
Cerebral Palsy 7
Disease 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Baclofen

Trials by Country

Trials by Country for Baclofen
Location Trials
United States 190
France 12
Canada 10
United Kingdom 9
Belgium 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Baclofen
Location Trials
New York 13
Texas 12
California 12
Pennsylvania 10
Minnesota 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Baclofen

Clinical Trial Phase

Clinical Trial Phase for Baclofen
Clinical Trial Phase Trials
Phase 4 20
Phase 3 14
Phase 2/Phase 3 6
[disabled in preview] 41
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Baclofen
Clinical Trial Phase Trials
Completed 50
Recruiting 18
Terminated 12
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Baclofen

Sponsor Name

Sponsor Name for Baclofen
Sponsor Trials
National Institute on Drug Abuse (NIDA) 6
VA Office of Research and Development 4
Medtronic 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Baclofen
Sponsor Trials
Other 96
Industry 30
NIH 12
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
US Army
Johnson and Johnson
Daiichi Sankyo
McKinsey
Harvard Business School
Cantor Fitzgerald
Cerilliant
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.